H. Kantarjian

Publications4,829
h-index210
Citations223,235
Highly Influential Citations8,154
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • J. Cortes
  • 3,074 Publications • 111,012 Citations
  • G. Garcia-Manero
  • 2,220 Publications • 70,509 Citations
  • F. Ravandi
  • 1,821 Publications • 41,543 Citations
  • E. Jabbour
  • 1,725 Publications • 31,534 Citations
  • Publications
  • Influence
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
TLDR
STI571 is well tolerated and has significant antileukemic activity in patients with CML in whom treatment with interferon alfa had failed and demonstrates the potential for the development of anticancer drugs based on the specific molecular abnormality present in a human cancer.
View on PubMed
Acute myeloid leukemia.
TLDR
Recent advances in understanding of the pathophysiology of acute myeloid leukemia (AML) and allied conditions are reviewed, including the advanced myelodysplastic syndromes (MDS), while Drs.
View on PubMed
Revised international prognostic scoring system for myelodysplastic syndromes.
TLDR
This revised IPSS-R comprehensively integrated the numerous known clinical features into a method analyzing MDS patient prognosis more precisely than the initial IPSS and should prove beneficial for predicting the clinical outcomes of untreated MDS patients and aiding design and analysis of clinical trials in this disease.
View on PubMed
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
TLDR
Imatinib was superior to interferon alfa plus low-dose cytarabine as first-line therapy in newly diagnosed chronic-phase CML and was better tolerated than combination therapy.
View on PubMed
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
TLDR
After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients.
View on PubMed
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
TLDR
Optimal responders to chronic myeloid leukemia treatment should continue therapy indefinitely, with careful surveillance, or they can be enrolled in controlled studies of treatment discontinuation once a deeper molecular response is achieved.
View on PubMed
Clinical effect of point mutations in myelodysplastic syndromes.
TLDR
Mutations in TP53, EZH2, ETV6, RUNX1, and ASXL1 are predictors of poor overall survival in patients with myelodysplastic syndromes, independently of established risk factors.
View on PubMed
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
TLDR
The BCR-ABL tyrosine kinase inhibitor STI571 is well tolerated and has substantial activity in the blast crises of CML and in Ph-positive ALL.
View on PubMed
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
TLDR
The acquisition of a T674I resistance mutation at the time of relapse demonstrates that FIP1L1-PDGFRalpha is the target of imatinib, and data indicate that the deletion of genetic material may result in gain-of-function fusion proteins.
View on PubMed
Decitabine improves patient outcomes in myelodysplastic syndromes
Aberrant DNA methylation, which results in leukemogenesis, is frequent in patients with myelodysplastic syndromes (MDS) and is a potential target for pharmacologic therapy. Decitabine indirectly…
View on Wiley
...
...